RxDoctor Payments Data

Ghary Gappelberg, MD

Internal Medicine · Woburn, MANPI 1487636304

Payments from drug & device makers

$1,282in general payments, 2019–2025

Across 73 payments — averaging $17.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$311
  • Boehringer Ingelheim$227
  • Lilly USA, LLC$156
  • Novo Nordisk$102
  • Johnson & Johnson$81
  • AstraZeneca$78
  • plus $327 from 10 others

What the payments were for

  • Food & beverage$1,282100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,282 in reported general payments places this provider in the 85th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$114,668
Medicare patients
235
Services billed
1,308

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide93$109,801
EliquisApixaban61$70,611
JardianceEmpagliflozin43$53,034
XareltoRivaroxaban15$16,695
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,822
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$7,327
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$4,852
Atorvastatin Calcium335$3,683
Rosuvastatin Calcium62$2,346
Ultra-Fine Short Pen NeedlePen Needle, Diabetic17$2,235
Metoprolol Succinate90$1,725
Lisinopril229$1,722
Wixela InhubFluticasone Propion/Salmeterol23$1,714
Olmesartan Medoxomil27$1,537
Omeprazole97$1,264

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$156$109,80193 claims
PfizerEliquis$311$70,61161 claims
Boehringer IngelheimJardiance$227$53,03443 claims
Johnson & JohnsonXarelto$81$16,69515 claims
GSKTrelegy Ellipta$20$7,82212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Woburn

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →